Healthcare distributor and services company McKesson (NYSE: MCK) fell short of the market’s revenue expectations in Q1 CY2026, but sales rose 6% year on year to $96.3 billion. Its non-GAAP profit of $11.69 per share was 1.1% above analysts’ consensus estimates.
Is now the time to buy MCK? Find out in our full research report (it’s free for active Edge members).
McKesson (MCK) Q1 CY2026 Highlights:
- Revenue: $96.3 billion vs analyst estimates of $101.6 billion (6% year-on-year growth, 5.3% miss)
- Adjusted EPS: $11.69 vs analyst estimates of $11.57 (1.1% beat)
- Adjusted EBITDA: $1.92 billion vs analyst estimates of $1.89 billion (2% margin, 1.7% beat)
- Adjusted EPS guidance for the upcoming financial year 2027 is $44.20 at the midpoint, in line with analyst estimates
- Operating Margin: 2.2%, in line with the same quarter last year
- Market Capitalization: $90.57 billion
StockStory’s Take
McKesson’s first quarter results fell short of analyst revenue expectations, with management attributing the shortfall to lower branded pharmaceutical revenues, including manufacturer price declines and a sequential dip in GLP-1 medication volumes. Despite these headwinds, sales grew year over year, supported by strength in specialty pharmaceutical distribution and expanded provider networks in oncology and multispecialty. CEO Brian Tyler acknowledged the impact of the Inflation Reduction Act’s initial wave of branded price changes on revenue, but highlighted double-digit operating profit growth in core segments and the successful integration of recent acquisitions as key drivers of the quarter’s performance. Tyler emphasized ongoing efficiency improvements and the company’s ability to maintain service reliability even during disruptive winter weather.
Looking ahead, McKesson’s guidance for the upcoming year centers on continued growth in specialty pharmaceuticals, the expansion of its oncology and multispecialty platforms, and increased demand for access solutions in its technology services segment. Management expects stable prescription utilization trends and further momentum from automation and AI-driven initiatives. CFO Britt Vitalone noted that the company’s outlook incorporates potential variability in product launches, biosimilar transitions, and the evolving mix of revenue from both organic and acquired sources. Tyler stated, “We enter the year from a position of strength with clear momentum across the business,” while also outlining ongoing portfolio actions, including the planned separation of the Medical-Surgical Solutions segment and further capital deployment through share repurchases.
Key Insights from Management’s Remarks
Management cited ongoing strength in specialty pharmaceuticals, successful provider network expansion, and recent portfolio actions as key drivers shaping the quarter’s results and outlook.
- Specialty pharmaceuticals momentum: Growth in specialty product distribution, particularly to health systems, remained a core driver, with management noting strong demand in both North American Pharmaceutical and oncology platforms.
- Provider network expansion: The U.S. Oncology Network added the highest number of providers since 2010, bolstered by the seamless integration of Core Ventures and PRISM Vision, enabling broader community and multispecialty care.
- Technology and automation investments: Advanced planning systems and automation, including AI-powered inventory management and Ambient Scribe documentation tools, contributed to operational efficiency, improving working capital and enhancing provider productivity.
- Medical-Surgical Solutions separation: Significant progress was made toward establishing Medical-Surgical Solutions as a standalone entity, including securing financing, onboarding Apollo as a minority investor, and finalizing transition service agreements.
- Impact of regulatory and policy changes: The first wave of price changes tied to the Inflation Reduction Act affected branded pharmaceutical revenues, but management emphasized continued strength in the company's value proposition to manufacturers and effective navigation of policy-related headwinds.
Drivers of Future Performance
McKesson’s outlook is shaped by ongoing specialty growth, investments in technology, and careful capital allocation amid evolving drug pricing dynamics.
- Specialty segment expansion: Management anticipates sustained growth in specialty pharmaceuticals and oncology platforms, with provider network additions and targeted acquisitions expected to drive revenue and margin gains. The integration of PRISM Vision and Core Ventures is projected to support double-digit operating profit increases in these segments.
- Technology solutions and automation: Continued investment in automation, AI-driven planning, and integrated access solutions is expected to improve operational efficiency and unlock new sources of value, particularly in the Prescription Technology Solutions segment. However, management noted that revenue from technology services may fluctuate due to the timing of product launches and changes in program support requirements.
- Regulatory and market variability: The company expects further variability from biosimilar launches, the impact of the Inflation Reduction Act, and shifts in branded drug pricing. These factors, along with the transition of Medical-Surgical Solutions to an independent entity, are expected to influence both short-term performance and long-term capital deployment strategy.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will focus on (1) the pace of provider network expansion, particularly in oncology and multispecialty platforms; (2) progress toward the separation and independent operation of Medical-Surgical Solutions; and (3) the impact of biosimilar launches and branded drug pricing changes on both revenue and margins. Continued adoption of automation and AI-driven technologies will also be closely monitored as potential catalysts for efficiency gains.
McKesson currently trades at $735.35, down from $753.84 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
